Kausik Ray is currently President of the European Atherosclerosis Society. Professor of Public Health, Director of Imperial Clinical Trials Unit-Global within the School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials –Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a post-doctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Prof Ray is also a member of the British Cardiovascular Society. He has served the EAS as a Consensus panel and EAS Executive Committee memeber. Professor Ray has either been the Principal Investigator and lead for several major medical trials, as well as international registries such as Da Vinci, Santorini, CLEAR Harmony, the ORION programme and BETONMACE as well as serving on the Executive Committee of many others. Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 94, an i10 of 236 and over 106,000 citations for his work in journals such as New England Journal of Medicine, The Lancet, JAMA, EHJ, Circulation and JACC. He has also been included in the Clarivate Analytics’ list of the top 1% most cited authors in all of global medicine in 2018, 2019, 2020 and 2021. Key original contributions which have influenced European and American guidelines as well as FDA and EMEA. Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH which includes 67 countries and 66,000 cases, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.